Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                       SECURITIES AND EXCHANGE ACT OF 1934

                                 March 15, 2002
                Date of Report (Date of earliest event reported)


                              NEOTHERAPEUTICS, INC.

             (Exact name of registrant as specified in its charter)

          Delaware                    000-28782                 93-0979187
(State or other Jurisdiction   (Commission File Number)       (IRS Employer
      of Incorporation)                                   Identification Number)

          157 Technology Drive                                    92618
           Irvine, California                                   (Zip Code)
(Address of principal executive offices)

                                 (949) 788-6700
              (Registrant's telephone number, including area code)

          (Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events

     On March 13, 2002, NeoTherapeutics, Inc. ("NeoTherapeutics") issued a press
release announcing the completion of an offering of 2,575,000 shares of its
common stock at a negotiated purchase price per share of $2.00 and warrants to
purchase up to 643,750 shares of its common stock at a purchase price per share
of $2.75 to investors for aggregate consideration of $5,150,000. During a public
conference call on March 14, 2002, NeoTherapeutics stated that it had completed
its current fundraising efforts. Following the conference call, NeoTherapeutics
received additional expressions of interest from investors, including some who
had participated in the completed offering, to provide additional financing on
the same terms. After considering these expressions of interest, on March 15,
2002, NeoTherapeutics agreed to issue an additional 525,000 shares of its common
stock and warrants to purchase up to 131,250 shares of its common stock to
investors on the same terms as the earlier offering, for aggregate additional
consideration of $1,050,000. The shares and warrants were issued pursuant to an
effective Registration Statement on Form S-3. NeoTherapeutics paid aggregate
fees and expenses of approximately $70,500 to a third party finder in connection
with this additional offering.

Item 7. Exhibits



Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                               NEOTHERAPEUTICS, INC.

Date:  March 26, 2002          By:    /s/ Samuel Gulko
                               Name:  Samuel Gulko

                               Title: Senior Vice President, Finance, Chief
                                      Financial Officer, Secretary and Treasurer